Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
28
09
2020
accepted:
18
02
2021
revised:
31
01
2021
pubmed:
17
3
2021
medline:
2
2
2022
entrez:
16
3
2021
Statut:
ppublish
Résumé
Clinical variables-age, family history, genetics-are used for prostate cancer risk stratification. Recently, polygenic hazard scores (PHS46, PHS166) were validated as associated with age at prostate cancer diagnosis. While polygenic scores are associated with all prostate cancer (not specific for fatal cancers), PHS46 was also associated with age at prostate cancer death. We evaluated if adding PHS to clinical variables improves associations with prostate cancer death. Genotype/phenotype data were obtained from a nested case-control Cohort of Swedish Men (n = 3279; 2163 with prostate cancer, 278 prostate cancer deaths). PHS and clinical variables (family history, alcohol intake, smoking, heart disease, hypertension, diabetes, body mass index) were tested via univariable Cox proportional hazards models for association with age at prostate cancer death. Multivariable Cox models with/without PHS were compared with log-likelihood tests. Median age at last follow-up/prostate cancer death was 78.0 (IQR: 72.3-84.1) and 81.4 (75.4-86.3) years, respectively. On univariable analysis, PHS46 (HR 3.41 [95% CI 2.78-4.17]), family history (HR 1.72 [1.46-2.03]), alcohol (HR 1.74 [1.40-2.15]), diabetes (HR 0.53 [0.37-0.75]) were each associated with prostate cancer death. On multivariable analysis, PHS46 (HR 2.45 [1.99-2.97]), family history (HR 1.73 [1.48-2.03]), alcohol (HR 1.45 [1.19-1.76]), diabetes (HR 0.62 [0.42-0.90]) all remained associated with fatal disease. Including PHS46 or PHS166 improved multivariable models for fatal prostate cancer (p < 10 PHS had the most robust association with fatal prostate cancer in a multivariable model with common risk factors, including family history. Adding PHS to clinical variables may improve prostate cancer risk stratification strategies.
Sections du résumé
BACKGROUND
Clinical variables-age, family history, genetics-are used for prostate cancer risk stratification. Recently, polygenic hazard scores (PHS46, PHS166) were validated as associated with age at prostate cancer diagnosis. While polygenic scores are associated with all prostate cancer (not specific for fatal cancers), PHS46 was also associated with age at prostate cancer death. We evaluated if adding PHS to clinical variables improves associations with prostate cancer death.
METHODS
Genotype/phenotype data were obtained from a nested case-control Cohort of Swedish Men (n = 3279; 2163 with prostate cancer, 278 prostate cancer deaths). PHS and clinical variables (family history, alcohol intake, smoking, heart disease, hypertension, diabetes, body mass index) were tested via univariable Cox proportional hazards models for association with age at prostate cancer death. Multivariable Cox models with/without PHS were compared with log-likelihood tests.
RESULTS
Median age at last follow-up/prostate cancer death was 78.0 (IQR: 72.3-84.1) and 81.4 (75.4-86.3) years, respectively. On univariable analysis, PHS46 (HR 3.41 [95% CI 2.78-4.17]), family history (HR 1.72 [1.46-2.03]), alcohol (HR 1.74 [1.40-2.15]), diabetes (HR 0.53 [0.37-0.75]) were each associated with prostate cancer death. On multivariable analysis, PHS46 (HR 2.45 [1.99-2.97]), family history (HR 1.73 [1.48-2.03]), alcohol (HR 1.45 [1.19-1.76]), diabetes (HR 0.62 [0.42-0.90]) all remained associated with fatal disease. Including PHS46 or PHS166 improved multivariable models for fatal prostate cancer (p < 10
CONCLUSIONS
PHS had the most robust association with fatal prostate cancer in a multivariable model with common risk factors, including family history. Adding PHS to clinical variables may improve prostate cancer risk stratification strategies.
Identifiants
pubmed: 33723363
doi: 10.1038/s41391-021-00341-4
pii: 10.1038/s41391-021-00341-4
pmc: PMC8387332
mid: NIHMS1675456
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
845-851Subventions
Organisme : NCI NIH HHS
ID : L30 CA231417
Pays : United States
Organisme : NIBIB NIH HHS
ID : K08 EB026503
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. https://doi.org/10.3322/caac.21262 .
doi: 10.3322/caac.21262
pubmed: 25651787
Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:1–7. https://doi.org/10.1136/bmj.j5757 .
doi: 10.1136/bmj.j5757
Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465–8. https://doi.org/10.1056/NEJMsb2000250 .
doi: 10.1056/NEJMsb2000250
pubmed: 32558473
pmcid: 7491201
Loeb S, Lilja H, Vickers A. Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol. 2016;26:459–65. https://doi.org/10.1097/MOU.0000000000000316 .
doi: 10.1097/MOU.0000000000000316
pubmed: 27262138
pmcid: 5035435
Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur Urol. 2018;74:204–10. https://doi.org/10.1016/j.eururo.2017.12.028 .
doi: 10.1016/j.eururo.2017.12.028
pubmed: 29331214
Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47. https://doi.org/10.1002/pros.2990170409 .
doi: 10.1002/pros.2990170409
pubmed: 2251225
Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a Nationwide Population-Based Study. J Natl Cancer Inst. 2016;108:djw110. https://doi.org/10.1093/jnci/djw110 .
doi: 10.1093/jnci/djw110
pubmed: 27400876
Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63–89. https://doi.org/10.14740/wjon1191 .
doi: 10.14740/wjon1191
pubmed: 31068988
pmcid: 6497009
Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991;83:551–7. https://doi.org/10.1093/jnci/83.8.551 .
doi: 10.1093/jnci/83.8.551
pubmed: 2005640
Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8. https://doi.org/10.1002/pros.22925 .
doi: 10.1002/pros.22925
pubmed: 25408531
Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016;43:560–5. https://doi.org/10.1053/j.seminoncol.2016.08.001 .
doi: 10.1053/j.seminoncol.2016.08.001
pubmed: 27899188
pmcid: 6986340
Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16:845. https://doi.org/10.1186/s12885-016-2891-z .
doi: 10.1186/s12885-016-2891-z
pubmed: 27842506
pmcid: 5109713
Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571–8. https://doi.org/10.1002/ijc.22788 .
doi: 10.1002/ijc.22788
pubmed: 17450530
pmcid: 2430098
Witte JS. Personalized prostate cancer screening: Improving PSA tests with genomic information. Sci Transl Med. 2010;2:62ps55. https://doi.org/10.1126/scitranslmed.3001861 .
doi: 10.1126/scitranslmed.3001861
pubmed: 21160075
Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, et al. The influence of BRCA2 mutation on localized prostate cancer. Nat Rev Urol. 2019;16:281–90. https://doi.org/10.1038/s41585-019-0164-8 .
doi: 10.1038/s41585-019-0164-8
pubmed: 30808988
Huynh-Le M-P, Fan CC, Karunamuni R, Martinez ME, Eeles RA, Kote-Jarai Z, et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021;12:1236. https://doi.org/10.1038/s41467-021-21287-0 .
doi: 10.1038/s41467-021-21287-0
pubmed: 33623038
pmcid: 7902617
Karunamuni R, Huynh-Le M-P, Fan C, Thompson W, Eeles R, Kote-Jarai Z, et al. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int J Cancer. 2020. https://doi.org/10.1002/ijc.33282 .
Discacciati A, Orsini N, Andersson S-O, Andren O, Johansson J-E, Mantzoros CS, et al. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. Ann Oncol. 2013;24:1912–8. https://doi.org/10.1093/annonc/mdt105 .
doi: 10.1093/annonc/mdt105
pubmed: 23508823
Rylander-Rudqvist T, Håkansson N, Tybring G, Wolk A. Quality and quantity of saliva DNA obtained from the self-administrated oragene method—a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomark Prev. 2006;15:1742–5. https://doi.org/10.1158/1055-9965.EPI-05-0706 .
doi: 10.1158/1055-9965.EPI-05-0706
Karunamuni RA, Huynh-Le M-P, Fan CC, Eeles RA, Easton DF, Kote-Jarai ZS, et al. The effect of sample size on polygenic hazard models for prostate cancer. Eur J Hum Genet. 2020. https://doi.org/10.1038/s41431-020-0664-2 .
Abdel-Rahman O. Prostate cancer incidence and mortality in relationship to family history of prostate cancer; findings from the PLCO Trial. Clin Genitourin Cancer. 2019. https://doi.org/10.1016/j.clgc.2019.05.015 .
Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal. 1999;5:99–112. https://doi.org/10.1023/A:1009691327335 .
doi: 10.1023/A:1009691327335
pubmed: 10408179
Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928–36. https://doi.org/10.1038/s41588-018-0142-8 .
doi: 10.1038/s41588-018-0142-8
pubmed: 29892016
pmcid: 6568012
Karunamuni RA, Huynh-Le M-P, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021:1–10. https://doi.org/10.1038/s41391-020-00311-2 .
Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society Guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98. https://doi.org/10.3322/caac.20066 .
doi: 10.3322/caac.20066
pubmed: 20200110
Goldgar DE, Easton DF, Cannon-albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600–8. https://doi.org/10.1093/jnci/86.21.1600 .
doi: 10.1093/jnci/86.21.1600
pubmed: 7932824
Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun M, et al. Family history and risk of fatal prostate cancer. Epidemiology. 1997;8:653–7. https://doi.org/10.1097/00001648-199710000-00007 .
doi: 10.1097/00001648-199710000-00007
pubmed: 9345665
Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30:143–8. https://doi.org/10.1007/s00345-011-0801-1 .
doi: 10.1007/s00345-011-0801-1
pubmed: 22116601
Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family history of breast or prostate cancer and prostate cancer risk. Clin Cancer Res. 2018;24:5910–7. https://doi.org/10.1158/1078-0432.CCR-18-0370 .
doi: 10.1158/1078-0432.CCR-18-0370
pubmed: 30082473
pmcid: 6279573
Adami HO, McLaughlin JK, Hsing AW, Wolk A, Ekbom A, Holmberg L, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control. 1992;3:419–25. https://doi.org/10.1007/BF00051354 .
doi: 10.1007/BF00051354
pubmed: 1525322
Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, et al. Alcohol consumption and prostate cancer incidence and progression: a Mendelian Randomisation Study. Int J Cancer. 2017;140:75–85. https://doi.org/10.1002/ijc.30436 .
doi: 10.1002/ijc.30436
pubmed: 27643404
Ratna A, Mandrekar P. Alcohol and cancer: mechanisms and therapies. Biomolecules. 2017;7. https://doi.org/10.3390/biom7030061 .
Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomark Prev. 2013;22:1102–9. https://doi.org/10.1158/1055-9965.EPI-12-1046 .
doi: 10.1158/1055-9965.EPI-12-1046
Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071–8. https://doi.org/10.1007/s00125-004-1415-6 .
doi: 10.1007/s00125-004-1415-6
pubmed: 15164171
Beckmann K, Crawley D, Nordström T, Aly M, Olsson H, Lantz A, et al. Association between antidiabetic medications and prostate-specific antigen levels and biopsy results. JAMA Netw Open. 2019;2:e1914689. https://doi.org/10.1001/jamanetworkopen.2019.14689 .
doi: 10.1001/jamanetworkopen.2019.14689
pubmed: 31693126
pmcid: 6865613
Hankinson SJ, Fam M, Patel NN. A review for clinicians: prostate cancer and the antineoplastic properties of metformin. Urol Oncol Semin Orig Investig. 2017;35:21–29. https://doi.org/10.1016/j.urolonc.2016.10.009 .
doi: 10.1016/j.urolonc.2016.10.009
NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2019.
NCCN Guidelines Version 1.2019 Older Adult Oncology. 2019.
Huynh-Le M-P, Fan CC, Karunamuni R, Walsh EI, Turner EL, Lane JA, et al. A genetic risk score to personalize prostate cancer screening, applied to population data. Cancer Epidemiol Biomark Prev. 2020;29:1731–8. https://doi.org/10.1158/1055-9965.epi-19-1527 .
doi: 10.1158/1055-9965.epi-19-1527
Huynh-Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, et al. Age dependence of modern clinical risk groups for localized prostate cancer—a population-based study. Cancer. 2020;126:1691–9. https://doi.org/10.1002/cncr.32702 .
doi: 10.1002/cncr.32702
pubmed: 31899813
DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308. https://doi.org/10.3322/caac.21340 .
doi: 10.3322/caac.21340
pubmed: 26910411